Medication Prescription and Dispense (MPD), published by Integrating the Healthcare Enterprise (IHE). This guide is not an authorized publication; it is the continuous build for version 1.0.0-comment-3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/IHE/pharm-mpd/tree/master and changes regularly. See the Directory of published versions
Built from commit e53380c3.

Glossary

The following key terms are used throughout this specification and are part of the IHE Glossary:

• Medication Order - any type of order for medicinal products - can be a proposal, a draft, a plan, a prescription or an instance order / Administration Request.

• Prescription - an order given by a clinician (usually physicians and in some particular cases pharmacists, nurses, etc.), for a medication to be dispensed to the patient and given to or taken by the patient.

• Dispense - the act of assigning a medication to a patient, normally as indicated in the authorizing prescription.

  Note: in many cases, the "dispense process" entails more activities, such as preparation, packaging, transport, etc. These vary according to the scenario - community or hospital, unit dose or traditional dispensing,… while the single differentiation activity that defines a Dispense is the assignment of a product that was available, to a specific patient.

• dosage form Form of the finished pharmaceutical product such as capsule, tablet, granulate, drops, suppository, etc.;

• dosage regimen Number of prescribed doses (e.g. in capsules of a specified strength, mg or ampoules, ml) within a given time period.

• dosage unit Typical dose taken by a patient; see also formulation dose Amount of a substance administered; see also formulation.

• dose Amount of a substance administered; see also formulation.

• formulation Form and composition under which a drug is presented as medicinal product; the f. is influenced by a number of factors such as the route of administration, chemical and biopharmaceutical properties of the substance (API), particle size (micronisation most often improves absorption); liquid f.s (especially aqueous solutions) can be administered by all routes but are bulky, more sensible to contamination and degradation and also more difficult to transport; if the drug is poorly soluble, suspensions (solid phase, i.e. particles distributed in liquid phase) or emulsions (two liquid phases, e.g. oil and water) may be produced; solid f.s appear most frequently as tablets (or orally disintegrating tablets) which frequently contain a number of excipients (e.g. lactose, cellulose), followed by capsules, usually made by hard or soft gelatine; capsules enclose the drug as powder or non-aqueous liquid within their two halves; other formulations can be prepared as liposomes, nanoparticles, or by microencapsulation, in particular if the API is poorly water soluble; semi-solid f.s are e.g. creams (oil/water emulsions) or ointments (water/oil emulsions) used in topical preparations for treatment of skin or mucous membranes; transdermal patches are applied like conventional sticking plasters and allow sustained drug release; coating is also a factor that influences the properties of a tablet;

• excipient Substances used in powder formulations in order to improve physical properties of the active ingredient such as stability, bioavailability or to enhance any other attribute; excipients are carriers or diluents (providing plug-forming properties, e.g. lactose, mannitol, sucrose, glucose, icing sugar), lubricants (reducing powder/metal adhesion, e.g. stearats, dimethicone, hydrogenated vegetable oils, liquid paraffin, polyethylene glycol, sodium stearyl fumarate), glidants (improving powder flow e.g. for capsule-filling machines, e.g. colloidal silicon dioxide, Ca silicate), wetting agents (improving water penetration, e.g. sodium lauryl sulfate, lecithin, polysorbate, polyoxyethylene stearate, sorbitan mono-oleate, polyethylene glycol 6000), disintegrants (producing disrup- tion of powder mass, e.g. sodium starch glycolate, alginic acid, croscarmellose, crospovidone, carmellose calcium, sodium carboxyaminopectin) and stabiliz- ers (improving product stability, e.g. ascorbic acid, ascorbyl palmitate, malic acid, propyl gallate, sodium metabisulphite);

• strength of medication ; syn. potency; amount of active pharmaceutical ingredient per unit (e.g., “50 mg tablet”) or concentration;

• solvent see excipients, residual solvents.

• virtual medicinal product (VMP) A conceptual definition of a medicine, opposed to a real-world marketed product. The focus is what the medicine is intended to be and not what is actually sold or dispensed. An example can be seen below:

Term	Description
Virtual Medicinal Product	Paracetamol 500 mg tablet — any tablet with 500mg of paracetamol
Actual Medicinal Product	Paracetamol Cinfa 500 mg tablet — a specific branded version
Real Medicinal Product	The actual box or blister of Paracetamol Cinfa on the shelf

Some defintions are or adpated from Dictionary of Pharmaceutical Medicine